Not long ago, a diagnosis of advanced cancer left doctors with little more than symptom control and hope. Over the course of a few of decades, however, that picture changed dramatically. Chemotherapy delivered the first meaningful survival gains, though at a steep cost in side effects, a cost later softened by a new generation of supportive drugs that made treatment safer and more tolerable. The mapping of the human genome then opened up an era of precision medicine, as whole-genome sequencing revealed mutations that could be directly targeted. Survival improved again, but a cure remained elusive: tumours kept finding new, resistant mutations to evade each targeted drug. It took a deeper understanding of the immune system to breach the next frontier: immunotherapy taught the body’s own defences to attack cancers once thought untreatable.
Now, a new contender has emerged that could rewrite the story once more: personalized mRNA tumour vaccines. Recent trial results suggest that the next chapter of the cancer treatment story may already be unfolding.
Evolution of treatment
Cancer treatment has advanced in successive waves. In the 1970s and 80s, chemotherapy became the cornerstone of oncology, improving outcomes across the board and curing diseases such as Hodgkin’s lymphoma and testicular cancer. The sequencing of the human genome and subsequent advances in molecular biology then enabled targeted therapies aimed at specific genetic abnormalities — HER2 in breast cancer, EGFR mutations in lung cancer, and many others.
The most dramatic transformation of the past two decades, however, came with immunotherapy. Checkpoint inhibitors such as pembrolizumab and nivolumab (drugs that block certain proteins on T-cells of the immune system, helping to attack cancer cells) changed the outlook for metastatic melanoma, a disease that had previously carried a dismal prognosis. What began in melanoma soon spread to lung, kidney, bladder, liver and head-and-neck cancers, reshaping treatment paradigms worldwide.
Immunotherapy has greatly impacted the management of blood cancers as well. Once primarily managed by chemotherapy, cancers like multiple myeloma and lymphoma, have entered the immunotherapy era through CAR-T cell therapy and bispecific antibodies (lab-made proteins that can attach to two different targets), producing outcomes unimaginable just a decade ago.
Today, personalised mRNA vaccines are poised to build on that foundation.
The melanoma breakthrough
The recent excitement around mRNA vaccines stems from the Phase III INTerpath-001 trial, which evaluated intismeran autogene (mRNA-4157/V940), a personalised mRNA vaccine. The study enrolled roughly 1,100 patients with high-risk melanoma who had undergone complete surgical removal of visible disease. They received either immunotherapy through pembrolizumab alone, or pembrolizumab combined with an individualised vaccine designed, using artificial intelligence, from the genetic profile of each patient’s own tumour. This vaccine essentially trained the patients’ immune systems to recognise and destroy unique mutations (neoantigens) on their tumour cells
The results were striking: the combination significantly improved both recurrence-free and distant metastasis-free survival compared with pembrolizumab alone. Earlier studies of the same strategy had already shown roughly a 49% reduction in the risk of recurrence or death, and a 59% reduction in the risk of distant metastasis or death, compelling evidence that a personalised vaccine can amplify the effect of existing immunotherapy.
For the first time, a personalised neoantigen-based mRNA therapy has succeeded in a large, randomized Phase III trial, validating a concept researcher have pursued for years.
How does it work?
Unlike traditional vaccines, which prevent infection, these are therapeutic vaccines, developed after a disease has been diagnosed, to help trigger the body’s immune system. Once a tumour is sequenced, sophisticated algorithms pick out the mutations unique to that patient’s cancer (neoantigens), providing the necessary information for production of customised mRNA constructs encoding these tumour-specific neoantigens. When injected, these mRNA constructs train the patient’s immune system, particularly the T cells, to recognise and destroy cancer cells carrying those exact mutations. In effect, every patient receives a vaccine made exclusively for their own cancer.
Cancer is increasingly understood as an ecosystem, shaped by interactions between tumour cells, the immune system and the surrounding microenvironment. Immunotherapy works by altering that ecosystem, changing the ‘immune soil’ in which cancer grows. Personalised mRNA vaccines may be the next step: directing the immune response with even greater precision.
Following on, from immunotherapy
The current moment resembles the early days of immunotherapy. When checkpoint inhibitors first showed unprecedented benefit in melanoma, many assumed the impact would stay confined to a handful of cancers. Instead, immunotherapy became a universal oncology platform, transforming treatment across tumour types.
mRNA vaccines appear to be following a similar trajectory. Melanoma, with its high mutational burden and strong response to immune-based approaches, served as the ideal proving ground. Researchers are now studying personalised vaccine strategies in lung, gastrointestinal, genitourinary and several other cancers.
If these trials succeed, the implications could be enormous. Future treatment may routinely involve genomic sequencing after surgery, followed by the rapid design of a patient-specific vaccine given alongside immunotherapy — aiming to wipe out microscopic residual disease before it can return. This is the essence of personalised cancer treatment.
The path ahead
Further automation of neoantigen discovery through AI and manufacturing techniques refined during the COVID-19 pandemic have demonstrated the capacity to generate sophisticated mRNA therapies at scale. Together, these advances are moving personalised cancer vaccines from concept to clinical reality.
Oncology has moved from supportive care to chemotherapy, from chemotherapy to targeted therapy, and from targeted therapy to immunotherapy. Personalised mRNA vaccines may mark the next great leap.
The battle against cancer is far from over. But history offers an encouraging precedent: melanoma announced the arrival of immunotherapy, and it may now be announcing the arrival of another revolutionary treatment platform. If the promise of mRNA tumour vaccines holds across multiple cancers, future generations may look back on this moment as the beginning of the next major transformation in cancer care.
(Dr. Harish P. is a consultant in medical oncology at Manipal Hospital Yelahanka. harish.p1@manipalhospitals.com)
Published – August 29, 2026 02:29 pm IST
